Semaglutide News and Research

Latest Semaglutide News and Research

Study examines the association of race and ethnicity with initiation of newer diabetes medications

Among patients with type 2 diabetes, minority racial/ethnic groups have higher rates of diabetes complications including cardiovascular disease, chronic kidney disease and hypoglycemia (low blood sugar).

25 Jan 2022

DPP4 protein: The connection between severe COVID-19 and diabetes

Researchers explore the relationship between DPP4 and diabetes targets in the management of COVID-19.

17 Jan 2022

An egg-derived SARS-CoV-2 vaccine and treatment for COVID-19 disease

A new study, posted to the medRxiv* preprint server, has focussed on the development of intranasal prophylaxis against SARS-CoV-2 infection.

11 Jan 2022

Fewer than 1 in 5 U.S. adults with Type 2 diabetes meet targets to reduce heart disease risk

Fewer than 1 in 5 adults with Type 2 diabetes in the U.S. are meeting targets to reduce heart disease risk. Fortunately, available therapies can help when combined with new approaches that address social determinants of health and other barriers to care, according to a new American Heart Association scientific statement published today in the Association's flagship journal Circulation.

10 Jan 2022

Flexibility may maximize the potency of peptides used to treat Type 2 diabetes

A little wiggle room might be just what the doctor ordered. New research suggests that the peptides - short chunks of protein - used to treat Type 2 diabetes may be more effective if they're able to flexibly move back and forth between different shapes.

23 Dec 2021

New study shows inequities in the use of heart disease-protective diabetes drug

A medication typically used for treating diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RA), could also be used to prevent cardiovascular disease and major cardiovascular events, but a new study showed inequities in its use based on race, ethnicity, and socioeconomic status.

17 Dec 2021

CellPort Software joins the Tetra Partner Network to help customers accelerate cell development and manufacturing

TetraScience, the R&D Data Cloud company, announced today that CellPort Software, a SaaS company that digitizes workflows for cell development and manufacturing, has joined the Tetra Partner Network to accelerate delivery of cell-based therapeutics.

From TetraScience, Inc. 15 Dec 2021

Safer, more effective therapies could help fight the obesity epidemic

Novel obesity treatments such as modulation of the gut microbiome and gene therapy are underutilized and could help fight the obesity epidemic, according to a new manuscript published in the Endocrine Society's journal, Endocrine Reviews.

26 Oct 2021

Drug company pipelines are filling up with new molecules to help people lose weight

Drugs that promise to help people lose weight have had a checkered past, such as the infamous fen-phen that was pulled from the market in 1997 after reports of heart valve damage. But now, drug company pipelines are filling up with new molecules that aim to help people safely shed extra pounds, according to a cover story in Chemical & Engineering News, an independent news outlet of the American Chemical Society.

21 Oct 2021

A mucoadhesive polymer with anti-SARS-COV-2 activity in vitro and in vivo

The team has evaluated a low molecular weight chitosan derivative as a candidate preventing the viral entry into mammalian nasal epithelial cells to limit the spread of COVID-19.

12 Oct 2021

Drug treatment decreases risk for severe COVID-19 outcomes in patients with Type 2 diabetes

A type of drug already used to treat obesity and Type 2 diabetes, when taken six months prior to the diagnosis of COVID-19, was associated with a decreased risk of hospitalization, respiratory complications and death in COVID-19 patients with Type 2 diabetes, according to researchers at Penn State College of Medicine.

27 Sep 2021

Drugs and surgery show promise for reducing long-term effects of obesity-related hypertension

Weight-loss medications and surgical procedures show promise for reducing the long-term effects of high blood pressure (also called hypertension) in people who are overweight or have obesity, according to a new American Heart Association scientific statement published today in the Association's journal Hypertension.

20 Sep 2021

Popular class of diabetes medications may be protective against glaucoma

A popular class of diabetes medications called GLP-1R agonists (Trulicity and Rybelsus) may also protect against glaucoma in diabetic patients, according to a new study led by researchers in the Scheie Eye Institute at the University of Pennsylvania's Perelman School of Medicine.

20 Sep 2021

Improving lifestyle and medication use could add healthy years of life after a heart attack

Adherence to lifestyle advice and medications could add seven healthy years of life after a heart attack, according to a study presented at ESC Congress 2021.

26 Aug 2021

Common weight-loss drug successfully targets fat in adults with obesity at high cardiovascular risk

Researchers at UT Southwestern announced successful results of a clinical trial for a commonly prescribed weight-loss drug called liraglutide.

4 Aug 2021

Diabetes drug’s new weight loss formula fuels cost-benefit debate

The long list of side effects that follow ads for the newer expensive drugs to treat Type 2 diabetes sometimes include an unusual warning: They might cause weight loss. That side effect is one that many people — especially those with Type 2 diabetes, which is associated with obesity — may desperately want.

30 Jul 2021

Study evaluates the difference in weight loss caused by two antidiabetic medications

Patients with Type 2 diabetes who were prescribed SGLT2 inhibitors lost more weight than patients who received GLP-1 receptor agonists, according to a University at Buffalo-led study.

2 Jul 2021

Vegan protein shakes may be viable alternatives to milk-based whey protein shakes

A study from the Centre for Nutraceuticals at the University of Westminster found that plant-based protein shakes may be potential viable alternatives to milk-based whey protein shakes, particularly in people with need of careful monitoring of glucose levels.

24 Jun 2021

Weight loss drug Wegovy approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Wegovy (semaglutide) injection (2.4 mg once weekly) as a chronic weight management treatment in obese or overweight adults with a weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), when used along with calorie restriction and physical activity. Wegovy, is a more potent version of Novo Nordisk's diabetes drug semaglutide.

4 Jun 2021

Asthma patients can benefit from type 2 diabetes medication

Type 2 diabetes patients who also have asthma are benefitting from a diabetes medication, typically given to help the pancreas produce more insulin, that also improves asthma symptoms and may reduce lung and airway inflammation.

21 May 2021

Semaglutide News and Research

Latest Semaglutide News and Research

Study examines the association of race and ethnicity with initiation of newer diabetes medications

DPP4 protein: The connection between severe COVID-19 and diabetes

An egg-derived SARS-CoV-2 vaccine and treatment for COVID-19 disease

Fewer than 1 in 5 U.S. adults with Type 2 diabetes meet targets to reduce heart disease risk

Flexibility may maximize the potency of peptides used to treat Type 2 diabetes

New study shows inequities in the use of heart disease-protective diabetes drug

CellPort Software joins the Tetra Partner Network to help customers accelerate cell development and manufacturing

Safer, more effective therapies could help fight the obesity epidemic

Drug company pipelines are filling up with new molecules to help people lose weight

A mucoadhesive polymer with anti-SARS-COV-2 activity in vitro and in vivo

Drug treatment decreases risk for severe COVID-19 outcomes in patients with Type 2 diabetes

Drugs and surgery show promise for reducing long-term effects of obesity-related hypertension

Popular class of diabetes medications may be protective against glaucoma

Improving lifestyle and medication use could add healthy years of life after a heart attack

Common weight-loss drug successfully targets fat in adults with obesity at high cardiovascular risk

Diabetes drug’s new weight loss formula fuels cost-benefit debate

Study evaluates the difference in weight loss caused by two antidiabetic medications

Vegan protein shakes may be viable alternatives to milk-based whey protein shakes

Weight loss drug Wegovy approved by FDA

Asthma patients can benefit from type 2 diabetes medication

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Semaglutide News and Research

Latest Semaglutide News and Research

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Redefining control and consistency in anaerobic microbiome workflows

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

Newsletters you may be interested in